View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 1, 2021updated 11 Jul 2022 9:48am

Trevena reports positive results from Covid-19 trial of TRV027

Approximately 70% of the subjects in the TRV027 arm had a decline in circulating D-dimer versus 27% in the placebo group.

Trevena has reported positive results from a proof-of-concept (PoC) clinical trial where its new AT1 receptor-selective agonist, TRV027, was well-tolerated in hospitalised Covid-19 patients.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

TRV027 is being analysed as a potential therapy for acute lung injury which causes acute respiratory distress syndrome (ARDS) and abnormal blood clotting in Covid-19 patients.

According to the trial data, TRV027 offered preliminary evidence of its potential to boost biomarker and clinical endpoints linked to disease severity and progression.

Imperial College London in the UK funded and led the trial, which received further support through the British Heart Foundation Imperial Centre for Research Excellence Award.

Mean change from baseline D-dimer levels at three days was the trial’s primary goal.

D-dimer is a biomarker used to assess the risk of abnormal clotting in the vascular system.

The rise in circulating D-dimer in Covid-19 patients is known to be a precise predictor of critical disease progression and mortality.

Nearly 70% of the subjects receiving TRV027 had a decline in circulating D-dimer as against 27% in the placebo arm.

Furthermore, TRV027 was linked to a 92% probability of a potential advantageous therapy effect based on a Bayesian model analysis recommended by the Data Monitoring and Safety Committee (DMSC) of the trial.

A post hoc analysis showed that subjects in the TRV027 arm had a 12-day reduction in the average length of hospital stay versus placebo while the median reduction was four days.

Trevena CEO president and Carrie Bourdow said: “I am pleased to announce the results from this analysis, which provide initial evidence of the therapeutic potential of TRV027 to improve Covid-19 patient outcomes.

“With the ACTIV and REMAP-CAP Covid-19 platform trials currently evaluating TRV027, and data expected as early as mid-2022, we look forward to building upon these promising results.”

The DMSC analysed the data in March and found no safety or efficacy concerns and recommended advancing TRV027 to a larger and wider trial with clinical efficacy outcomes.

In addition, the DMSC advised closing subject recruitment at the interim analysis enrolling nearly 30 patients before reaching the target required to analyse statistically significant therapy differences.

Currently, TRV027 is being analysed in two global, multi-site, multi-arm efficacy studies, namely the ACTIV-4 Host Tissue trial in the US and the REMAP-CAP trial in the UK.

In July, Trevena reported that the first subject was enrolled in the US National Institutes of Health (NIH)-funded ACTIV-4 Host Tissue trial of TRV027 for Covid-19.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology